← All stocks

Contineum Therapeutics, Inc.

CTNM Scheduled selling only
CIK 0001855175 #2951 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$1.86M
$385.01K on a plan · $1.47M straight out of an exercise
Sold at will
$0.00
0 of 31 sales
Net
−$1.86M
$0.00 against sales at will

By person

3 insiders · 31 transactions
0.4×

Carmine N. Stengone holds only 0.4 times base salary in stock. $283.33K of shares against $655.62K in salary for 2025.

Salary from the company's own proxy. The shares are what Carmine N. Stengone last reported holding, valued at $16.46, the price Class A Common Stock was last bought or sold at on the open market here, on 8 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Lorrain Daniel S.
Chief Scientific Officer
$1.13M (19) scheduled
−$1.13M
135,202
0.5853%
$2.22M
−23.1%
Stengone Carmine N.
CEO and President
$401.38K (7) scheduled
−$401.38K
17,217
0.0745%
$283.33K
0.0%
Watkins Tim
CMO & Head of Development
$322.56K (5) scheduled
−$322.56K
8,961
0.0388%
$147.47K
0.0%
Insider
Date
Role
Action
Shares
Price
Amount
Stengone Carmine N.
8 Sep 2026
CEO and President
Sold after exercise
2,500
$16.46
$41.14K
Stengone Carmine N.
3 Aug 2026
CEO and President
Sold after exercise
2,500
$16.01
$40.03K
Lorrain Daniel S.
9 Jul 2026
Chief Scientific Officer
Sold after exercise
25
$16.00
$400.00
Stengone Carmine N.
8 Jul 2026
CEO and President
Sold after exercise
2,500
$16.00
$40.00K
Lorrain Daniel S.
8 Jul 2026
Chief Scientific Officer
Sold after exercise
1,015
$16.00
$16.24K
Lorrain Daniel S.
1 Jul 2026
Chief Scientific Officer
Sold after exercise
2,501
$16.24
$40.61K
Lorrain Daniel S.
1 Jul 2026
Chief Scientific Officer
Sold after exercise
5,852
$15.67
$91.68K
Stengone Carmine N.
30 Jun 2026
CEO and President
Sold after exercise
10,000
$16.01
$160.08K
Watkins Tim
30 Jun 2026
CMO & Head of Development
Sold after exercise
10,833
$16.02
$173.59K
Lorrain Daniel S.
30 Jun 2026
Chief Scientific Officer
Sold after exercise
28,826
$16.04
$462.29K
Watkins Tim
2 Mar 2026
CMO & Head of Development
Sold after exercise
3,611
$15.02
$54.22K
Lorrain Daniel S.
25 Feb 2026
Chief Scientific Officer
Sold after exercise
3,824
$16.01
$61.23K
Stengone Carmine N.
25 Feb 2026
CEO and President
Sold after exercise
2,700
$16.02
$43.24K
Lorrain Daniel S.
24 Feb 2026
Chief Scientific Officer
Sold after exercise
4,300
$16.03
$68.94K
Stengone Carmine N.
24 Feb 2026
CEO and President
Sold after exercise
4,400
$16.02
$70.49K
Lorrain Daniel S.
19 Feb 2026
Chief Scientific Officer
Sold after exercise
100
$16.00
$1.60K
Lorrain Daniel S.
11 Feb 2026
Chief Scientific Officer
Sold after exercise
400
$16.00
$6.40K
Stengone Carmine N.
11 Feb 2026
CEO and President
Sold after exercise
400
$16.00
$6.40K
Watkins Tim
28 Jan 2026
CMO & Head of Development
Sold after exercise
811
$14.48
$11.75K
Watkins Tim
28 Jan 2026
CMO & Head of Development
Sold after exercise
2,800
$14.09
$39.44K
Watkins Tim
29 Dec 2025
CMO & Head of Development
Sold after exercise
3,611
$12.06
$43.56K

What was left out

Form 4 filings counted 33
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 10
Sales straight out of an exercise 21
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 89,339
History held since 11 Apr 2024